Virtus ETF Advisers LLC Grows Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Virtus ETF Advisers LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,310 shares of the biopharmaceutical company’s stock after acquiring an additional 673 shares during the period. Virtus ETF Advisers LLC’s holdings in Halozyme Therapeutics were worth $349,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Halozyme Therapeutics during the fourth quarter worth about $60,054,000. Capital World Investors acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $35,773,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Halozyme Therapeutics by 141.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock worth $47,470,000 after purchasing an additional 581,475 shares during the period. Raymond James Financial Inc. acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $21,838,000. Finally, Vanguard Group Inc. increased its holdings in Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after purchasing an additional 386,618 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on HALO. HC Wainwright restated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Friday. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $62.89.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now owns 33,611 shares in the company, valued at $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,200 shares of company stock valued at $1,286,568. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $60.49 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $37.97 and a 12 month high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market capitalization of $7.47 billion, a PE ratio of 17.64, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The business’s fifty day moving average price is $60.50 and its 200 day moving average price is $55.12.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.